TRINO, STEFANIA
 Distribuzione geografica
Continente #
NA - Nord America 542
EU - Europa 477
AS - Asia 235
AF - Africa 44
SA - Sud America 1
Totale 1.299
Nazione #
US - Stati Uniti d'America 542
GB - Regno Unito 150
VN - Vietnam 102
SE - Svezia 101
CN - Cina 67
DE - Germania 60
IT - Italia 56
IN - India 28
SG - Singapore 28
FR - Francia 23
IE - Irlanda 21
TG - Togo 21
CH - Svizzera 17
RU - Federazione Russa 15
ZA - Sudafrica 12
EE - Estonia 9
FI - Finlandia 6
UA - Ucraina 6
BE - Belgio 5
NG - Nigeria 5
CI - Costa d'Avorio 4
BG - Bulgaria 3
JO - Giordania 3
PL - Polonia 3
AT - Austria 2
EG - Egitto 2
IR - Iran 2
CL - Cile 1
HK - Hong Kong 1
JP - Giappone 1
KR - Corea 1
LB - Libano 1
UZ - Uzbekistan 1
Totale 1.299
Città #
Southend 138
Chandler 80
Dong Ket 70
Fairfield 70
Ashburn 58
Ann Arbor 32
Woodbridge 30
Seattle 28
Princeton 25
Wilmington 22
Dublin 21
Houston 21
Lomé 21
Singapore 19
Cambridge 16
Bern 15
Bologna 14
Florence 12
Nanjing 12
New York 12
Westminster 12
Beijing 11
Padova 11
Jinan 10
Turin 10
Medford 9
Saint Petersburg 7
Hebei 6
Helsinki 6
Abeokuta 5
Bremen 5
Brussels 5
Shenyang 5
Abidjan 4
Berlin 4
Redwood City 4
Amman 3
Changsha 3
Falls Church 3
Grafing 3
Mountain View 3
Mülheim 3
Nanchang 3
Sofia 3
Boardman 2
Cairo 2
Haikou 2
Hyderabad 2
Jiaxing 2
Kunming 2
Leawood 2
Monmouth Junction 2
Mumbai 2
Ningbo 2
Norwalk 2
Paris 2
Pordenone 2
Rubano 2
San Diego 2
Tianjin 2
Bühl 1
Central 1
Cesena 1
Changchun 1
Chicago 1
Esslingen am Neckar 1
Forlì 1
Frankfurt Am Main 1
Frankfurt am Main 1
Fremont 1
Fuzhou 1
Guangzhou 1
Hangzhou 1
Jacksonville 1
Kiev 1
Las Vegas 1
Lincoln 1
London 1
Los Angeles 1
Olalla 1
Orange 1
Peterborough 1
Plauen 1
Radomsko 1
Redmond 1
Roubaix 1
Taiyuan 1
Tokyo 1
Vancouver 1
Warsaw 1
Waterford 1
Totale 917
Nome #
CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients. 177
ARF Loss, a Negative Prognostic Factor in Philadelphia-Positive Acute Lymphoblastic Leukemia, May Be Efficiently Overcome by the Small Molecule MDM2 Antagonist RG7112 156
BCR-ABL1-Positive Acute Lymphoblastic Leukemia Patients Treated with Only TKI Vs Conventional Chemo Plus TKI Therapy Show Similar DNA Alterations At Relapse Targeting Key Regulators of Tumor Suppression, Cell Cycle Control, and Lymphoid/B-Cell Development 138
Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: A new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients 122
An exploratory study by DMET array identifies a germline signature associated with imatinib response in gastrointestinal stromal tumor 118
TP53 Alterations Including Missense Mutations, Aberrant Exon-Junctions and Internal Intron Retentions Are Frequent and May Contribute to MDM2 Antagonist-Resistance in B-Acute Lymphoblastic leukemia 104
Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia. 100
Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia. 97
LOSS OF CDKN2A GENE IS A POOR PROGNOSTIC MARKER IN ADULT BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS 91
MULTIPLEX PCR TO RAPIDLY IDENTIFY IKZF1 (IKAROS) GENE BREAKPOINTS IN BCRABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 82
SEVERAL FUSION TRANSCRIPTS ARE DETECTED BY NEXT GENERATION PAIRED END TRANSCRIPTOMIC RE-SEQUENCING APPROACH IN ADULT BCR-ABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 75
NEXT GENERATION PAIRED END TRANSCRIPTOMIC RE-SEQUENCING TECHNOLOGY REVEALS NOVEL COMMON GENETIC ALTERATIONS IN THE HEDGEHOG PATHWAY IN ADULT BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 72
Totale 1.332
Categoria #
all - tutte 2.987
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.987


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020289 43 10 4 25 31 21 31 25 41 20 18 20
2020/2021234 33 5 3 0 7 7 9 16 19 10 6 119
2021/2022239 23 3 10 13 28 19 4 13 7 22 50 47
2022/2023349 31 68 14 41 17 28 13 18 45 9 34 31
2023/202471 7 13 0 8 6 17 3 5 1 2 5 4
2024/202530 30 0 0 0 0 0 0 0 0 0 0 0
Totale 1.332